BRAF
BRAF (B-Raf proto-oncogene, serine/threonine kinase) is a protein-coding gene that encodes a cytoplasmic serine/threonine-protein kinase in the RAF family.
BRAF (B-Raf proto-oncogene, serine/threonine kinase) is a protein-coding gene that encodes a cytoplasmic serine/threonine-protein kinase in the RAF family. It is a central component of the RAS–RAF–MEK–ERK mitogen-activated protein kinase (MAPK) pathway, which regulates cell proliferation, differentiation, survival, and migration. Following activation by RAS, BRAF can promote phosphorylation and activation of MEK proteins, leading to downstream ERK signaling and changes in gene expression.
Activating BRAF mutations are important drivers in multiple cancers. The best-known alteration is BRAF V600E, which produces a constitutively active kinase and enables MAPK signaling independently of normal upstream regulation. BRAF alterations are particularly relevant in melanoma, colorectal cancer, thyroid carcinoma, histiocytic and dendritic cell neoplasms, and other tumors. They may serve as diagnostic, prognostic, or treatment-selection biomarkers and can influence the use of BRAF- and MEK-directed therapies. BRAF signaling is also affected by interactions with RAS, EGFR, PTEN, and other components of growth-factor and intracellular signaling networks.
Where the papers sit
22 papers from the last 6 months study BRAF directly · updated from PubMed 15 Nov 2026
Study type 2 clinical trials · 9 observational · 4 human data · 6 preclinical · 1 unclassified
Themes 4 themes
-
BRAF-Mutant Melanoma Care
Treatment of BRAF V600E melanoma is moving toward biomarker-guided sequencing of BRAF/MEK inhibition, surgery, and other disease-specific strategies rather than a single standard pathway. Progression-free survival, overall response, and survival vary with pTERT subtype, disease site, and treatment strategy, including brain and in-transit metastases. Circulating thymidine kinase and preoperative ctDNA are being evaluated to refine prognosis and treatment timing. Vemurafenib-based therapy also shows activity in BRAF-mutant hairy cell leukemia, extending the approach beyond melanoma.
7 papers · 31.8%
-
BRAF Inhibitor Discovery
Structure-guided discovery is generating new BRAF-directed scaffolds rather than focusing only on established inhibitors. Chalcone–quinazolinone, benzofuran–thiadiazole urea, and pyrimidinopyrimidine compounds are being screened against BRAF V600E, with dual VEGFR-2 activity and apoptosis as recurring goals. Molecular docking and dynamics support binding hypotheses, while caspase 9 links candidate activity to apoptotic signaling. The work remains early, with computational prioritization and biochemical or cellular validation preceding clinical translation.
5 papers · 22.7%
-
BRAF-Driven Lung and Brain Tumors
BRAF-altered lung and brain tumors are being defined by alteration type rather than treated as one molecular entity. BRAF fusions create TKI vulnerabilities but can also mediate resistance, while post-osimertinib EGFR-mutant NSCLC is prompting osimertinib–selumetinib combination testing. Comprehensive genomic profiling and consensus guidance are central to selecting therapy across non-small-cell lung cancer and glioma. Cutaneous toxicity from BRAF/MEK inhibitors remains a practical constraint, leaving optimal sequencing and combination durability open.
4 papers · 18.2%
-
Others — Cancer Biomarkers and Therapeutics
Mutant-BRAF degradation, colorectal cancer prognosis, image-derived biomarkers, and treatment guidance appear together without a single disease focus. The recurring theme is molecular stratification: molecular responses, systemic inflammation, histopathology features, and defined genomic alterations are used to separate risk or treatment benefit. Evidence ranges from in silico and preliminary in vitro work to real-world survival analyses, canine therapy, and pediatric thyroid guidance. No consistent therapeutic direction emerges, and validation across cohorts remains the shared unmet need.
6 papers · 27.3%
Papers
The 22 papers from the last 6 months that study BRAF directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BRAF-Mutant Melanoma Care (7)
- Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. Acta oncologica (Stockholm, Sweden) · 9 Sept 2026 PMID 42714248
- Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 4 Aug 2026 PMID 42550831
- Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 15 Jul 2026 PMID 42456530
- Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study. International journal of dermatology · 8 Jul 2026 PMID 42415286
- Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy. European journal of cancer (Oxford, England : 1990) · 23 Jun 2026 PMID 42335571
- Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood advances · 17 Jun 2026 PMID 42308249
- Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
BRAF Inhibitor Discovery (5)
- Discovery of chalcone-quinazolinone hybrids as BRAF kinase inhibitors with potential anticancer activity: Design, synthesis, biological evaluation, and molecular modeling studies. Bioorganic chemistry · 5 Nov 2026 PMID 42987746
- Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies. Bioorganic & medicinal chemistry · 6 Aug 2026 PMID 42561779
- DF-S4: Disentangled FiLM-Conditioned Molecular Generation Using the S4 Architecture. Journal of chemical information and modeling · 23 Jul 2026 PMID 42489643
- Unveiling Large-Scale Kinase-Centric Protein-Protein Interactions through a Knowledge-Informed Workflow. Journal of chemical information and modeling · 10 Jul 2026 PMID 42427025
- Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. ChemMedChem · 28 May 2026 PMID 42208521
BRAF-Driven Lung and Brain Tumors (4)
- BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Aug 2026 PMID 42546514
- BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions. Neuro-oncology · 9 Jun 2026 PMID 42261252
- Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
- Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. Clinical pharmacology and therapeutics · 24 May 2026 PMID 42177750
Others — Cancer Biomarkers and Therapeutics (6)
- In silico prioritization with preliminary in vitro assessment of UV-328-associated molecular responses in colorectal cancer cells. Functional & integrative genomics · 5 Nov 2026 PMID 42986495
- Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 26 Sept 2026 PMID 42798176
- Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
- Updated Dutch 2026 pediatric differentiated thyroid carcinoma guideline: aligning with Europe. European journal of endocrinology · 23 Jul 2026 PMID 42489130
- A molecular glue to take down mutant BRAF. Science signaling · 14 Jul 2026 PMID 42447212
- Spatial biomarker discovery via interpretable semantic learning in histopathology. Cancer cell · 11 Jun 2026 PMID 42276049
By study type
Clinical trials (2)
- Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial. Clinical cancer research : an official journal of the American Association for Cancer Research · 4 Aug 2026 PMID 42550831
- Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD. European journal of cancer (Oxford, England : 1990) · 27 May 2026 PMID 42202477
Observational studies and case reports (9)
- Systemic inflammation and prognosis in patients with RAS/BRAF wild-type metastatic colorectal cancer receiving anti-EGFR therapy: A real-world cohort study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 26 Sept 2026 PMID 42798176
- Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology. Acta oncologica (Stockholm, Sweden) · 9 Sept 2026 PMID 42714248
- BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) · 3 Aug 2026 PMID 42546514
- Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 15 Jul 2026 PMID 42456530
- Association Between pTERT Promoter Mutation Subtypes and Survival Outcomes in BRAF-Mutant Metastatic Melanoma Treated With BRAF/MEK Inhibitors: An Exploratory Study. International journal of dermatology · 8 Jul 2026 PMID 42415286
- Response and survival in unresectable in-transit metastatic melanoma according to treatment strategy. European journal of cancer (Oxford, England : 1990) · 23 Jun 2026 PMID 42335571
- Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood advances · 17 Jun 2026 PMID 42308249
- Secondary BRAF-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of clinical pathology · 9 Jun 2026 PMID 42264920
- Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data. Clinical pharmacology and therapeutics · 24 May 2026 PMID 42177750
Human data, design not indexed (4)
- Updated Dutch 2026 pediatric differentiated thyroid carcinoma guideline: aligning with Europe. European journal of endocrinology · 23 Jul 2026 PMID 42489130
- A molecular glue to take down mutant BRAF. Science signaling · 14 Jul 2026 PMID 42447212
- Unveiling Large-Scale Kinase-Centric Protein-Protein Interactions through a Knowledge-Informed Workflow. Journal of chemical information and modeling · 10 Jul 2026 PMID 42427025
- Spatial biomarker discovery via interpretable semantic learning in histopathology. Cancer cell · 11 Jun 2026 PMID 42276049
Preclinical: animal, cell and lab studies (6)
- Discovery of chalcone-quinazolinone hybrids as BRAF kinase inhibitors with potential anticancer activity: Design, synthesis, biological evaluation, and molecular modeling studies. Bioorganic chemistry · 5 Nov 2026 PMID 42987746
- In silico prioritization with preliminary in vitro assessment of UV-328-associated molecular responses in colorectal cancer cells. Functional & integrative genomics · 5 Nov 2026 PMID 42986495
- Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
- Novel benzofuran-1,3,4-thiadiazole aryl urea hybrids as dual VEGFR-2/BRAF inhibitors: anticancer activity, apoptosis induction, and molecular modeling studies. Bioorganic & medicinal chemistry · 6 Aug 2026 PMID 42561779
- DF-S4: Disentangled FiLM-Conditioned Molecular Generation Using the S4 Architecture. Journal of chemical information and modeling · 23 Jul 2026 PMID 42489643
- Design and Synthesis of Pyrimidino[4,5-d]Pyrimidine-Based Compounds as Potent B-RAF V600E Inhibitors. ChemMedChem · 28 May 2026 PMID 42208521
Unclassified: not yet indexed with MeSH (1)
- BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions. Neuro-oncology · 9 Jun 2026 PMID 42261252
Written from 22 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.